Dublin, Nov. 02, 2018 (GLOBE NEWSWIRE) — The “Investigation Report on China Entecavir 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The number of people infected with hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese are estimated to die of liver damage and liver cancer caused by chronic Hepatitis B, causing a loss of over CNY100 billion for society.
Entecavir, an oral drug of oral deoxyguanosine, was developed by BristolMyers Squibb and approved to enter the market by FDA in Mar. 2005. Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd got CFDA’s approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs which promote market growth to some extent. According to a market survey, the annual sales value of Entecavir in China rose from CNY1126.04 million in 2013 to CNY 1995.69 million in 2017 and CAGR during this period reached up to 15.38%. Entecavir made by SinoAmerican Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 39.82% in 2017 for sales value and 23.96% for sales volume.
Compared with the original nucleoside analogue, Entecavir has stronger antiviral effects, faster onset, fewer side effects and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over a long term. As is known to all, new drug’s entering into the anti HBV drug market are bound to pose a threat to old ones, forming a new competitive landscape. Due to the lack of new antiviral drugs for Hepatitis B in a long time, the market demand is far from being satisfied. Therefore, Entecavir is estimated to enjoy good market prospects and its sales value will keep growing in the next few years.
Topics covered:
- Market size of Entecavir in China
- Competitive landscape of Entecavir in Chinese market
- Price of Entecavir made by different manufacturers in China
- Market outlook of Entecavir in China
Key Topics Covered:
1 Related Concepts of Entecavir
1.1 Indications for Entecavir
1.2 Development History of Entecavir in China
1.3 Governmental Approval for Entecavir in China
2 Survey on Sales Status of Entecavir in China, 2013-2017
2.1 Sales Value of Entecavir
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Entecavir
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Entecavir by Dosage Form in China, 2013-2017
2.3.1 Capsules
2.3.2 Tablets
3 Major Manufacturers of Entecavir in China, 2013-2017
3.1 Market Share of Major Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.’s Entecavir in China
3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir in China
3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Jiangxi Qingfeng Pharmaceutical Co., Ltd.’s Entecavir in China
3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Suzhou Dawnrays Pharmaceutical Co., Ltd.’s Entecavir in China
3.6 Fujian Cosunter Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Fujian Cosunter Pharmaceutical Co., Ltd.’s Entecavir in China
4 Prices of Entecavir in China, 2017-2018
4.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Runzhong)
4.2 Sino-American Shanghai Squibb Pharmaceuticals Ltd. (Baraclude)
4.3 Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Weiliqing)
4.4 Suzhou Dawnrays Pharmaceutical Co., Ltd. (Leiyide)
4.5 Fujian Cosunter Pharmaceutical Co., Ltd. (Enganding)
5 Market Outlook of Entecavir in China, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/research/b7ks85/investigation?w=12
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infectious Diseases Drugs
